Technical Analysis for BCYC - Bicycle Therapeutics plc

Grade Last Price % Change Price Change
C 23.92 6.79% 1.52
BCYC closed up 6.79 percent on Friday, March 5, 2021, on 1.11 times normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical BCYC trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Bullish Engulfing Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 6.79%
Stochastic Reached Oversold Weakness 6.79%
Wide Bands Range Expansion 6.79%
Older End-of-Day Signals for BCYC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bicycle Therapeutics plc Description

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Diseases Immunology Oncology Hematology Ophthalmology Tumors Immune Checkpoint Cancer Research Search Technology

Is BCYC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 33.0
52 Week Low 10.26
Average Volume 158,697
200-Day Moving Average 19.70
50-Day Moving Average 24.55
20-Day Moving Average 26.19
10-Day Moving Average 24.59
Average True Range 2.35
ADX 17.62
+DI 18.68
-DI 24.27
Chandelier Exit (Long, 3 ATRs ) 24.54
Chandelier Exit (Short, 3 ATRs ) 27.72
Upper Bollinger Band 30.18
Lower Bollinger Band 22.21
Percent B (%b) 0.21
BandWidth 30.45
MACD Line -0.50
MACD Signal Line 0.00
MACD Histogram -0.4965
Fundamentals Value
Market Cap 509.61 Million
Num Shares 21.3 Million
EPS -14.16
Price-to-Earnings (P/E) Ratio -1.69
Price-to-Sales 30.77
Price-to-Book 3.85
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.18
Resistance 3 (R3) 31.03 28.46 29.97
Resistance 2 (R2) 28.46 26.61 28.54 29.57
Resistance 1 (R1) 26.19 25.47 27.33 26.34 29.16
Pivot Point 23.62 23.62 24.19 23.69 23.62
Support 1 (S1) 21.35 21.77 22.48 21.50 18.68
Support 2 (S2) 18.78 20.63 18.85 18.27
Support 3 (S3) 16.51 18.78 17.87
Support 4 (S4) 16.66